Seiji Katayama

Title: Seiji Katayama: Innovator in Pharmaceutical Chemistry

Introduction

Seiji Katayama is a notable inventor based in Toyonaka, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that target specific receptors in the human body. His work has implications for treating various medical conditions, showcasing the importance of innovation in healthcare.

Latest Patents

One of Seiji Katayama's key patents is for a quinazolinone derivative. This optically active form of quinazolinone derivatives is represented by a specific general formula. The compound exhibits selective antagonism for the M3 muscarinic receptor and has a depressant action on the frequency of rhythmic bladder contractions. This makes it useful for treating conditions such as pollakiuria and urinary incontinence. He holds 1 patent related to this innovative compound.

Career Highlights

Seiji Katayama is associated with Dainippon Sumitomo Pharma Co., Ltd., where he has been instrumental in advancing pharmaceutical research and development. His expertise in medicinal chemistry has led to breakthroughs that enhance the quality of life for patients suffering from urinary disorders.

Collaborations

Throughout his career, Seiji has collaborated with talented individuals such as Masami Muraoka and Kazuki Matsui. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Seiji Katayama's contributions to pharmaceutical chemistry, particularly through his patent on quinazolinone derivatives, highlight the critical role of inventors in advancing medical science. His work continues to impact the treatment of urinary conditions, demonstrating the value of innovation in healthcare.